Consensus Statements among European Sleep Surgery Experts on Snoring and Obstructive Sleep Apnea: Part 1 Definitions and Diagnosis.
Ewa Olszewska, Andrea De Vito, Peter Baptista...
https://pubmed.ncbi.nlm.nih.gov/38256636/Actively Recruiting
Led by Medical University of Bialystok · Updated on 2026-07-23
120
Participants Needed
1
Research Sites
N/A
Total Duration
Obstructive sleep apnea OSA is a common sleep disorder marked by repeated airway blockage during sleep, leading to intermittent lack of oxygen, inflammation, oxidative stress, and higher risks of heart and metabolic diseases. Although current diagnostic methods like polysomnography are effective, their availability is limited and they do not fully predict disease severity or how patients respond to treatment. This study aims to find and confirm blood biomarkers that could improve screening, diagnosis, risk assessment, and monitoring for adults with OSA. The study involves 120 adults who will undergo clinical evaluation and overnight sleep studies. Those with moderate-to-severe OSA will be randomly assigned to receive either immediate or delayed positive airway pressure PAP therapy for 6 months, while participants without OSA serve as controls. Blood samples will be collected at scheduled visits to analyze various inflammatory, metabolic, oxidative stress, and other biomarkers. The study will assess how these biomarkers relate to OSA severity and how they change with PAP treatment. Participants will be evaluated at baseline, 3 months, and 6 months, including clinical assessments and blood sampling. PAP therapy adherence will be monitored using device-recorded data. Researchers will measure differences in biomarker levels between OSA and control groups, track changes during therapy, and examine the relationship between biomarkers and OSA severity. The study seeks to enhance understanding of OSA biology and support development of personalized diagnostic and management tools.
CONDITIONS
Identification of Biomarkers of Obstructive Sleep Apnea.
E
Ewa Olszewska, M.D., Prof.
A
Agnieszka Polecka, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medical University of Bialystok
Lead Sponsor
National Science Centre, Poland
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 baseline visit including clinical evaluation and overnight polysomnography
Duration - 6 months
Participants with moderate-to-severe OSA receive positive airway pressure (PAP) therapy either immediately or after a 3-month delay. Controls do not receive PAP therapy. Clinical assessments and blood samples are collected at baseline, 3 months, and 6 months to evaluate biomarker changes and therapy adherence.
3 visits at baseline, 3 months, and 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Ewa Olszewska, Andrea De Vito, Peter Baptista...
https://pubmed.ncbi.nlm.nih.gov/38256636/Ewa Olszewska, Tymoteusz Marek Pietrewicz, Magdalena Świderska...
https://pubmed.ncbi.nlm.nih.gov/36430593/Paul E Peppard, Terry Young, Jodi H Barnet...
https://pubmed.ncbi.nlm.nih.gov/23589584/Mohit, Manendra Singh Tomar, Fabrizio Araniti...
https://pubmed.ncbi.nlm.nih.gov/36504723/Ewa Olszewska, B Tucker Woodson
https://pubmed.ncbi.nlm.nih.gov/30828637/Ewa Olszewska, Andrea De Vito, Clemens Heiser...
https://pubmed.ncbi.nlm.nih.gov/39336926/Adam V Benjafield, Najib T Ayas, Peter R Eastwood...
https://pubmed.ncbi.nlm.nih.gov/31300334/Leila Kheirandish-Gozal, David Gozal
https://pubmed.ncbi.nlm.nih.gov/30678164/Ewa Olszewska, Andrea De Vito, Carlos O'Connor-Reina...
https://pubmed.ncbi.nlm.nih.gov/38610848/Medical University of Bialystok
Lead Sponsor
National Science Centre, Poland
Collaborating Sponsor